María Victoria
Mateos Manteca
Monash University
Melbourne, AustraliaPublikationen in Zusammenarbeit mit Forschern von Monash University (12)
2024
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Blood Advances, Vol. 8, Núm. 2, pp. 388-398
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609
2022
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
2021
-
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
British Journal of Haematology
-
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
British Journal of Haematology, Vol. 193, Núm. 3, pp. 561-569
2020
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
2018
-
Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis
JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397
2017
-
Differentiation stage of myeloma plasma cells: Biological and clinical significance
Leukemia, Vol. 31, Núm. 2, pp. 382-392
2016
-
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
New England Journal of Medicine, Vol. 375, Núm. 8, pp. 754-766
2015
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2014
-
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Blood, Vol. 123, Núm. 26, pp. 4136-4142